Luis Malpica

995 total citations
37 papers, 489 citations indexed

About

Luis Malpica is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Luis Malpica has authored 37 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 18 papers in Oncology and 8 papers in Immunology. Recurrent topics in Luis Malpica's work include Lymphoma Diagnosis and Treatment (20 papers), Viral-associated cancers and disorders (11 papers) and T-cell and Retrovirus Studies (7 papers). Luis Malpica is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Viral-associated cancers and disorders (11 papers) and T-cell and Retrovirus Studies (7 papers). Luis Malpica collaborates with scholars based in United States, Peru and Mexico. Luis Malpica's co-authors include Grant R. Williams, Hyman B. Muss, Gabriel Aleixo, Kirsten A. Nyrop, Shlomit Strulov Shachar, Stephan Moll, Roberto N. Miranda, Brady Beltrán, Jorge J. Castillo and Mario L. Marques‐Piubelli and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Luis Malpica

30 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luis Malpica United States 9 184 168 124 106 68 37 489
Daisuke Kurita Japan 14 79 0.4× 262 1.6× 143 1.2× 254 2.4× 20 0.3× 80 704
Masahito Tokunaga Japan 11 18 0.1× 89 0.5× 269 2.2× 34 0.3× 5 0.1× 38 424
Tomomi Ichikawa Japan 14 181 1.0× 117 0.7× 343 2.8× 21 0.2× 47 0.7× 28 697
M. Raphaël France 11 50 0.3× 51 0.3× 117 0.9× 72 0.7× 29 418
Yasuhiko Miyazaki Japan 13 20 0.1× 123 0.7× 142 1.1× 41 0.4× 35 516
M Bisson France 8 114 0.6× 74 0.4× 77 0.6× 41 0.4× 32 341
Nishi Shah United States 10 17 0.1× 104 0.6× 58 0.5× 22 0.2× 1 0.0× 57 429
Kenneth W. Zamkoff United States 13 27 0.1× 146 0.9× 163 1.3× 130 1.2× 38 470
Hiroaki Ida Japan 10 96 0.5× 26 0.2× 101 0.8× 10 0.1× 18 348

Countries citing papers authored by Luis Malpica

Since Specialization
Citations

This map shows the geographic impact of Luis Malpica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Malpica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Malpica more than expected).

Fields of papers citing papers by Luis Malpica

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Malpica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Malpica. The network helps show where Luis Malpica may publish in the future.

Co-authorship network of co-authors of Luis Malpica

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Malpica. A scholar is included among the top collaborators of Luis Malpica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Malpica. Luis Malpica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strati, Paolo, Lei Feng, Jason R. Westin, et al.. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nature Communications. 16(1). 7300–7300.
2.
3.
Pradeep, Roshini, Ranjit Nair, Luis Malpica, et al.. (2024). Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS). Blood. 144(Supplement 1). 7776–7776.
4.
Westin, Jason R., Loretta J. Nastoupil, Ranjit Nair, et al.. (2024). Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7044–7044. 4 indexed citations
5.
Martínez‐Cordero, Humberto, et al.. (2024). Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology. 99(8). 1586–1594. 7 indexed citations
6.
Malpica, Luis, Mario L. Marques‐Piubelli, Brady Beltrán, et al.. (2024). EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management. American Journal of Hematology. 99(10). 2002–2015. 5 indexed citations
7.
Wu, Susan, Jie Xu, Penny Fang, et al.. (2024). Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder. International Journal of Dermatology. 64(2). 385–389.
8.
Candelaria, Myrna, et al.. (2024). Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients. International Journal of Molecular Sciences. 25(17). 9328–9328. 2 indexed citations
9.
Nair, Ranjit, Jingjing Liu, Chen Zhou, et al.. (2024). An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL. Blood. 144(Supplement 1). 455–455. 1 indexed citations
10.
Wu, Susan, Penny Fang, Sairah Ahmed, et al.. (2023). Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Advances in Radiation Oncology. 8(6). 101279–101279. 4 indexed citations
11.
12.
Iyer, Swaminathan P., Lei Feng, Jie Xu, et al.. (2023). TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis. Clinical Lymphoma Myeloma & Leukemia. 23. S468–S469. 3 indexed citations
13.
Cai, Qingqing, Jun Zhu, Yuqin Song, et al.. (2023). Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).. Journal of Clinical Oncology. 41(16_suppl). 7503–7503. 1 indexed citations
14.
15.
Aguilar, Cristian, Brady Beltrán, Domingo Morales, et al.. (2022). Isolated cardiac valve involvement in smoldering adult T-cell leukemia/lymphoma. Cardiovascular Pathology. 64. 107513–107513. 2 indexed citations
16.
Qiu, Lianqun, Guilin Tang, Shaoying Li, et al.. (2022). <i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 108(6). 1604–1615. 23 indexed citations
17.
Malpica, Luis, Daniel Enríquez, Camila Peña, et al.. (2021). An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. Leukemia & lymphoma. 63(2). 315–325. 5 indexed citations
18.
Valcárcel, Bryan, Gabriel De la Cruz Ku, Luis Malpica, & Daniel Enríquez. (2021). Clinical features and outcome of Aeromonas sobria bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru. PLoS ONE. 16(8). e0255910–e0255910. 10 indexed citations
19.
Aleixo, Gabriel, Shlomit Strulov Shachar, Kirsten A. Nyrop, et al.. (2019). Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 145. 102839–102839. 219 indexed citations
20.
Malpica, Luis, et al.. (2019). Regulatory T cells and IgE expression in duodenal mucosa of Strongyloides stercoralis and human T lymphotropic virus type 1 co-infected patients. PLoS neglected tropical diseases. 13(6). e0007415–e0007415. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daisuke Kurita Breakdown of academic impact, for papers by Masahito Tokunaga Breakdown of academic impact, for papers by Tomomi Ichikawa Breakdown of academic impact, for papers by M. Raphaël Breakdown of academic impact, for papers by Yasuhiko Miyazaki Breakdown of academic impact, for papers by M Bisson Breakdown of academic impact, for papers by Nishi Shah Breakdown of academic impact, for papers by Kenneth W. Zamkoff Breakdown of academic impact, for papers by Hiroaki Ida
Rankless by CCL
2026